According to our latest study, "Asthma Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Medications, Route of Administration, and Distribution Channels," the asthma drugs market size is projected to grow from US$ 24,239.17 million in 2021 to US$ 34,136.10 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028. The report highlights the key factors driving the market and prominent players with their developments.

 

Asthma is a chronic respiratory disease blocking the lungs' airways because of inflammation, mucus production, and tightening of muscles. Asthma can usually be managed with rescue inhalers to treat symptoms (salbutamol) and controller inhalers that prevent symptoms (steroids). Severe cases may require longer-acting inhalers that keep the airways open (formoterol, salmeterol, tiotropium) and inhalant steroids.  The growing incidence of asthma and other breathing syndromes is one of the significant elements increasing the market's progress. The growth of the asthma drugs market is primarily attributed to the growing environmental implications & genetic implications of air pollution and more vulnerability in specific ethnic groups. On the other hand, unmet medical needs and lack of treatment adherence are hindering the market's growth

 

Get Sample PDF at:- https://www.theinsightpartners.com/sample/TIPRE00021879/

 

 

 

Exposure to an allergy or irritant, infections, exercise, emotional stress, and other conditions are all potential triggers. When the symptoms of asthma become unbearable, an asthma attack ensues. Attacks can happen out of nowhere and range in severity from mild to life-threatening. Asthma is managed with rescue inhalers to treat symptoms and controller inhalers that prevent symptoms. Severe cases may require longer-acting inhalers that keep the airways open (formoterol, salmeterol, tiotropium), as well as inhalant steroids. Asthma medication comes in several forms, including tablets, injections, liquids, and inhalers; and it falls into two groups: bronchodilators and anti-inflammatories.

A few of the most notable companies occupying a considerable share of the market are AstraZeneca, TEVA PHARMACEUTICAL INDUSTRIES LTD, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Koninklijke Philips N.V., Sanofi, Pfizer Inc., Novartis AG, and Abbott.

Market leaders are involved in partnerships, product launches, acquisitions, and other strategies to improve their performance and consolidate the market position. The companies are focusing on organic strategies such as product launches, and product approvals. Inorganic growth strategies witnessed in the market were acquisitions, collaboration, and partnerships. These growth strategies have aided the market players in the expansion of their business enhanced their geographic presence. Additionally, growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.

A few of the vital developments in the asthma drugs market are mentioned below:

Year

News

Jan-2022

GlaxoSmithKline plc got product approval from the US Food and Drug Administration (FDA) for a 40 mg prefilled syringe of Nucala (mepolizumab) for appropriate children aged 6 to 11 years old who have severe eosinophilic asthma (SEA). Nucala can now be given by a child’s health care provider or administered at home by a caregiver once trained by a health care professional. Nucala is an add-on, prescription maintenance treatment for patients 6 years and older with severe eosinophilic asthma.

Dec-2021

AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has got approval in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine.2-5 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase II and III clinical trials which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts, allergic status, and fractional exhaled nitric oxide (FeNO).

Nov-2021

AstraZeneca agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). The agreement ensured continued patient access to these established medicines. Covis Pharma previously acquired the rights to the respiratory medicines Alvesco, Omnaris, and Zetonna from AstraZeneca in 2018.

Jun-2021

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced its U.S. launch of the first generic version of twice-daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

 

About The Insight Partners

 

The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as healthcare, media, and telecommunication.

 

Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.

 

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of type, end user, etc. This helps our clients gain a deeper analytical understanding of various research topics.

 

Contact Us

If you have any queries about this report or would like further information, please contact us:

 

§  North America: +1 646 491 9876

§  Asia Pacific:                 +91 20 6727 8686

§  Email:                           sales@theinsightpartners.com